bupropion ER / Generic mfg. - LARVOL DELTA

RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE) (clinicaltrials.gov) - P4 | N=120 | Not yet recruiting | Sponsor: Mayo Clinic

Biomarker • New P4 trial • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Naltrexone/Bupropion, Liraglutide, or Semaglutide as Adjuvant Therapy After Metabolic and Bariatric Surgery: An Observational Study. (PubMed, Obes Sci Pract) - "Adverse effects were minor and reflected clinical trial nonsurgical cohorts. Adjuvant OMM conferred additional significant weight loss in patients with RWG or SWL in both primary and conversional surgical procedures and all three OMM studied should be considered as part of MBS aftercare."

Journal • Observational data • Gastrointestinal Disorder • Genetic Disorders • Obesity

Use of Naltrexone-Bupropion in Persons with Overweight/Obesity and Symptoms of Depression (OBESITY WEEK 2025) - " Data from 511 participants with symptoms of depression were pooled from four, 56-week, double-blind, randomized controlled trials that compared naltrexone ER (16 or 32mg/d) + bupropion ER (360 mg/d) to placebo in subjects with overweight/obesity... Adults with overweight/obesity and symptoms of depression lost more weight with NB-ER than with placebo, and depression improved in both treatment groups. Rates of psychiatric safety signals did not differ from that of placebo-treated patients. NB-ER appears to be both safe and effective when offered to patients with mild to moderate symptoms of depression."

CNS Disorders • Depression • Genetic Disorders • Mood Disorders • Obesity • Psychiatry • Suicidal Ideation

6 and 12 Month Outcomes Among Individuals Prescribed Oral Anti-Obesity Medications via Telehealth (OBESITY WEEK 2025) - "The oral AOMs were various combinations* of metformin, topiramate, bupropion XL, and naltrexone, prescribed to participants for off-label use based on their individual weight loss goals, medication history, and preferences. Individuals who were prescribed oral AOMs as part of a personalized, holistic weight loss program via a national telehealth platform experienced weight loss considered clinically meaningful at over 5% at 6 months and over 10% at 12 months. Published clinical trials of oral AOMs have found weight loss of 5-7% IBW at 6 months and approximately 9% IBW at 12 months. Results indicate that such telehealth-accessible interventions can help millions of American adults affected by overweight and obesity."

Clinical • Genetic Disorders • Obesity

Healthcare Cost & Use Trajectories of Patients Prescribed Phentermine vs. Newer Obesity Medications (OBESITY WEEK 2025) - " Using a nationwide commercial claims dataset spanning 2012-2023, we identified cohorts of incident users of phentermine (n=133,460), phentermine-topiramate-ER (n=13,967), bupropion-naltrexone-SR (n=28,693), and the obesity-labeled version of liraglutide (n=48,953)... Compared to generic phentermine, initiation of second and early third generation OMs was associated with a sizeable increase in annual healthcare costs up to 3 years after starting treatment, with prescription drug prices driving much of the increase. Acute care use was largely similar across groups, suggesting no increased risk of serious adverse events for phentermine users. These findings support the current use of phentermine as a first-line agent to contain population-level cost impacts of newer OMs."

Clinical • HEOR • Cardiovascular • Diabetes • Genetic Disorders • Hypertension • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: Yale University

New P1 trial • Genetic Disorders • Obesity • Tobacco Cessation

BUPROPION EXTENDED-RELEASE TOXICITY RESULTING IN CARDIOGENIC SHOCK AND FATALITY (CHEST 2025) - "Three hours post-ingestion, the patient developed multiple seizures, treated with lorazepam and levetiracetam. Bupropion has gained favorability due to its side effect profile compared to other antidepressant classes. However, given the potential for toxicity, it is imperative for clinicians to be aware of bupropion's specific toxidrome, promptly recognize overdoses, and take proactive measures including early consideration of ECMO and CRRT. Further research is needed to develop consistent and effective treatment protocols for bupropion overdose."

Cardiomyopathy • Cardiovascular • CNS Disorders • Depression • Epilepsy • Hematological Disorders • Metabolic Disorders • Psychiatry • Thrombosis • Ventricular Tachycardia

Cutaneous hypersensitivity reaction to bupropion: clinical diagnosis and treatment strategy (ECNP 2025) - "Her psychiatric history extended over five years, during which she had been diagnosed with bipolar disorder and treated with various psychotropic agents, including lamotrigine (200 mg/day), quetiapine (25 mg/day), and sertraline (50 mg/day). Her most recent regimen included escitalopram (20 mg/day) and buspirone (30 mg/day), which she discontinued on her own initiative due to lack of perceived benefit...Considering the prominence of motivational deficits and anhedonia, bupropion extended-release (150 mg/day) was initiated...Subsequently, low-dose aripiprazole (2.5 mg/day) was added for augmentation...This case also highlights the importance of vigilant monitoring during the early phases of antidepressant initiation, especially in elderly patients (3), who may have altered pharmacokinetics and pharmacodynamics, predisposing them to adverse drug reactions. The clinical decision to switch to duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), proved..."

Clinical • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • Tobacco Cessation

Esketamine enabled deprescribing of most medications in a highly polymedicated patient with treatment-resistant depression (ECNP 2025) - "Despite sequential and combined use of high-dose antidepressants—including venlafaxine, mirtazapine, bupropion (Elontril), vortioxetine (Brintellix), duloxetine, escitalopram, and clomipramine (Anafranil)—as well as mood stabilizers (valproate, lamotrigine, lithium) and various anxiolytics, the patient failed to achieve symptom remission...This significant improvement allowed for the gradual discontinuation of all antidepressant medications and mood stabilizers, maintaining only low-dose quetiapine at night for sleep...Esketamine facilitated not only symptom remission but also the deprescription of complex medication regimens, optimizing both clinical outcomes and medication burden in refractory depression. The observed relapse after discontinuation and subsequent improvement upon re-initiation emphasize the importance of maintenance strategies and individualized long-term management for patients with TRD.[3]"

Clinical • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • Suicidal Ideation

Improving Efficacity of Sleeve Gastrectomy With Naltrexone/Bupropion Extended-release Tablet (clinicaltrials.gov) - P4 | N=108 | Recruiting | Sponsor: Laval University | Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Disorder • Genetic Disorders • Obesity

Atypical Severe Bupropion and Olanzapine Toxicity with Delayed Cardiac Decompensation and Transient Tachycardia Requiring Extracorporeal Membrane Oxygenation. (PubMed, J Emerg Med) - "A 28-year-old male presented after being found unconscious with clonic jerks and multiple empty bupropion XL 300 mg and olanzapine 10 mg bottles. This case supports the utility of ECMO in treating bupropion-induced cardiogenic shock and supports the ineffectiveness of sodium bicarbonate in bupropion-induced QRS widening. This patient had full neurologic recovery despite features that could be mistaken for brain death."

Journal • Cardiovascular • CNS Disorders • Epilepsy

Serotonin Syndrome Without Overdose: Polypharmacy-Induced Toxicity in a Medically Stable Young Adult. (PubMed, Cureus) - "He had been on stable outpatient doses of escitalopram 20 mg and bupropion XL 150 mg daily for over six months, with naltrexone 50 mg added three months earlier for off-label psychiatric use. This case emphasizes the importance of clinical vigilance in patients with neuropsychiatric comorbidities on centrally acting agents, even in the absence of recent medication changes. It illustrates that even therapeutic combinations of serotonergic and modulating agents can precipitate life-threatening toxicity."

Journal • Cardiovascular • CNS Disorders • Critical care • Depression • Epilepsy • Major Depressive Disorder • Mood Disorders • Movement Disorders • Obsessive-Compulsive Disorder • Psychiatry

TTOP: Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment (clinicaltrials.gov) - P2 | N=126 | Active, not recruiting | Sponsor: Joseph Valentino, MD | Recruiting ➔ Active, not recruiting

Enrollment closed • Oncology • Tobacco Cessation

Managing attention-deficit/hyperactivity disorder in a breastfeeding mother: A case report. (PubMed, Pharmacotherapy) - "This case underscores the feasibility of cautiously escalating stimulant therapy in a breastfeeding mother with ADHD, showing improved functioning in the mother without immediate effects on development in the infant. Significant gaps persist in guidance for postpartum ADHD care, underscoring the need for more research to inform safe and effective treatment."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Management Challenges in Severe Serotonin Syndrome: A Case Report and Literature Review (APA 2025) - "Her husband reported that she had taken approximately 70 Wellbutrin XL 150mg following...When attempting to taper off sedation, Dexmedetomidine, due to its prolonged use for over 24 hours,it caused withdrawal symptoms, resulting in severe agitation and vital signs instability...We selected Guanfacine over Clonidine which was an effective option as well; but could lead to hypotension (reported rates as high as 44%)...High-dose Benzodiazepines were then initiated as the mainstay of treatment with Lorazepam dose 2mg IV QID. In addition, Gabapentin was added for potentially offering presynaptic inhibitory effects on Glutamatergic neurons...Hydralazine should have been avoided due to its significant inhibitory effects on MAO which could exacerbate serotonin toxicity. Instead, the patient would benefit of rapidly-acting medications with short half-lives, such as Esmolol, particularly to mitigate the risk of hypotension."

Case report • Clinical • Review • Addiction (Opioid and Alcohol) • Anesthesia • Cardiovascular • CNS Disorders • Depression • Epilepsy • General Anxiety Disorder • Hypotension • Major Depressive Disorder • Mood Disorders • Psychiatry

Cpap as an Augmentation Agent for Depressive Symptoms in Active-Duty Navy Sailors an Important Perspective Shift for Psychiatric Tunnel Vision (APA 2025) - "The patient strongly desired to continue his career in the US Navy but experienced difficulty meeting the demands of his career due to persistent fatigue, amotivation, and difficulty concentrating, despite pharmacotherapy with fluoxetine 80mg and Adderall XR® 20mg...A combination of fluoxetine 40mg and bupropion XL 300mg led to only mild improvement in his anxiety and depressive symptoms over 5 months... Low mood, low energy, and amotivation are often treated by a psychiatrist as depressive symptoms. These cases highlight the importance of keeping an open, transdiagnostic, differential diagnosis. Given the wide prevalence of OSA, it may be beneficial to screen patients with depressive symptoms for sleep disorders early in their course of treatment."

ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Depression • Fatigue • Major Depressive Disorder • Mood Disorders • Obstructive Sleep Apnea • Personality Disorder • Psychiatry • Respiratory Diseases • Sleep Disorder • Suicidal Ideation

Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder. (clinicaltrials.gov) - P3 | N=237 | Terminated | Sponsor: University of British Columbia | N=178 ➔ 237 | Completed ➔ Terminated; Recruitment was stopped before the planned sample size was reached owing to the Covid-19 pandemic and expiration of funding.

Enrollment change • Trial termination • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors (clinicaltrials.gov) - P3 | N=422 | Recruiting | Sponsor: University of Rochester NCORP Research Base | Trial completion date: Sep 2025 ➔ Dec 2025

Trial completion date • Breast Cancer • Fatigue • Hematological Malignancies • Oncology • Solid Tumor

Appropriate use of the fixed-dose, extended-release combination of naltrexone and bupropion as treatment for obesity in primary care. (PubMed, Obes Pillars) - "Unlike monotherapy with its component drugs, NB-ER is optimized for the treatment of obesity. The appropriate use of NB-ER should consider the specific characteristics and adiposity-related complications of an individual."

Journal • Review • Addiction (Opioid and Alcohol) • CNS Disorders • Genetic Disorders • Obesity • POMC-null Obesity • Psychiatry • Tobacco Addiction

Cardiovascular safety of fixed-dose extended-release naltrexone/bupropion in clinical practice. (PubMed, Obes Pillars) - "The fixed-dose extended-release combination of naltrexone/bupropion (NB-ER) is indicated to treat overweight and obesity in adults as an adjunct to a reduced-calorie diet and increased physical activity. Conclusions from this study must be interpreted in the context of certain assumptions related to PS methodology and use of lorcaserin as an active comparator. Causal interpretations for the cardiovascular safety of NB-ER should be evaluated further in a prospective, randomized, blinded, controlled clinical trial."

Clinical • Journal • Cardiovascular • Genetic Disorders • Myocardial Infarction • Obesity

INTRAVENOUS LIPID EMULSION FOR CARDIOGENIC SHOCK DUE TO BUPROPION TOXICITY (SCCM 2025) - "Description: We present the case of a 27-year-old female with a medical history of bipolar disorder who was brought to the emergency room following ingestion of 30 extended-release bupropion tablets of 150 mg strength. The rapid improvement in hemodynamic stability and cardiac function observed in this patient suggests that ILE may play a valuable role in the management of severe bupropion toxicity leading to cardiogenic shock. Further studies are needed to establish standardized guidelines for the use of ILE in this context and to better understand its efficacy and safety profile."

Bipolar Disorder • Cardiovascular • CNS Disorders • Hypotension • Mood Disorders • Psychiatry • Respiratory Diseases • Ventricular Tachycardia

BUPROPION OVERDOSE LEADING TO CARDIOGENIC SHOCK SUCCESSFULLY MANAGED WITH VA ECMO (SCCM 2025) - "Description: 21-year-old male with a medical history of anxiety and depression presented following an intentional overdose of extended release bupropion, ingesting an unknown quantity of 300mg tablets. ECG abnormalities may prompt treatment with sodium bicarbonate or lipid emulsion. If cardiogenic shock ensures, VA ECMO may be lifesaving."

Cardiovascular • CNS Disorders • Depression • Epilepsy • Psychiatry • Respiratory Diseases • Sexual Disorders • Ventricular Tachycardia

Characterization of the effect of naltrexone/bupropion on body composition. (PubMed, Diabetes Obes Metab) - "NB-induced weight loss is associated with significant reductions in total percent fat mass, increase in total percent lean mass, and change in lean-to-fat mass ratio, in comparison to placebo. Larger studies are needed to further elucidate the clinical significance of these changes and impact of a potentially healthier metabolism."

Journal • Genetic Disorders

Bupropion for the Prevention of Postpartum Smoking Relapse (clinicaltrials.gov) - P4 | N=200 | Recruiting | Sponsor: University of Minnesota | Trial completion date: Jan 2025 ➔ Jan 2026 | Trial primary completion date: Jan 2025 ➔ Jan 2026

Trial completion date • Trial primary completion date

Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use (clinicaltrials.gov) - P=N/A | N=19 | Completed | Sponsor: Thomas Jefferson University | N=40 ➔ 19 | Active, not recruiting ➔ Completed

Biomarker • Enrollment change • Trial completion • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • CRP • IL10 • IL2